MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145246 | Name: SDM-8

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SDM-8 is also known as SynVesT-1. SynVesT-1 is a PET radiopharmaceutical that binds to the synaptic vesicle protein 2A (SV2A) and serves as a biomarker of synaptic density with widespread clinical research applications in psychiatry and neurodegeneration.

Chemical Structure

SDM-8
SDM-8
CAS#2242777-37-1

Theoretical Analysis

MedKoo Cat#: 145246

Name: SDM-8

CAS#: 2242777-37-1

Chemical Formula: C17H16F2N2O

Exact Mass: 302.1231

Molecular Weight: 302.32

Elemental Analysis: C, 67.54; H, 5.33; F, 12.57; N, 9.27; O, 5.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SDM-8; SDM8; SDM 8; SYNVEST-1;
IUPAC/Chemical Name
(R)-4-(3,5-difluorophenyl)-1-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one
InChi Key
JLTZBYZOWVBLBQ-AWEZNQCLSA-N
InChi Code
1S/C17H16F2N2O/c1-11-8-20-3-2-12(11)9-21-10-14(6-17(21)22)13-4-15(18)7-16(19)5-13/h2-5,7-8,14H,6,9-10H2,1H3/t14-/m0/s1
SMILES Code
CC1=CN=CC=C1CN2C[C@H](CC2=O)C3=CC(F)=CC(F)=C3
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 302.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Carson RE, Naganawa M, Toyonaga T, Koohsari S, Yang Y, Chen MK, Matuskey D, Finnema SJ. Imaging of Synaptic Density in Neurodegenerative Disorders. J Nucl Med. 2022 Jun;63(Suppl 1):60S-67S. doi: 10.2967/jnumed.121.263201. PMID: 35649655. 2: Desmond KL, Lindberg A, Garcia A, Tong J, Harkness MB, Dobrota E, Smart K, Uribe C, Meyer JH, Houle S, Strafella AP, Li S, Huang Y, Vasdev N. First-in- Human PET Imaging of [18F]SDM-4MP3: A Cautionary Tale. Mol Imaging. 2023 Sep 8;2023:8826977. doi: 10.1155/2023/8826977. PMID: 37719326; PMCID: PMC10504053. 3: Spurrier J, Nicholson L, Fang XT, Stoner AJ, Toyonaga T, Holden D, Siegert TR, Laird W, Allnutt MA, Chiasseu M, Brody AH, Takahashi H, Nies SH, Pérez- Cañamás A, Sadasivam P, Lee S, Li S, Zhang L, Huang YH, Carson RE, Cai Z, Strittmatter SM. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci Transl Med. 2022 Jun;14(647):eabi8593. doi: 10.1126/scitranslmed.abi8593. Epub 2022 Jun 1. PMID: 35648810; PMCID: PMC9554345. 4: Booth TC. Editorial: Rising stars in neuroradiology: 2022. Front Radiol. 2024 Jan 5;3:1349600. doi: 10.3389/fradi.2023.1349600. PMID: 38249157; PMCID: PMC10796443. 5: Martin SL, Uribe C, Strafella AP. PET imaging of synaptic density in Parkinsonian disorders. J Neurosci Res. 2024 Mar;102(3):e25253. doi: 10.1002/jnr.25253. Epub 2023 Oct 10. PMID: 37814917. 6: Jafari-Sabet M, Amiri S, Aghamiri H, Fatahi N. Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus. Neurobiol Learn Mem. 2022 Jul;192:107638. doi: 10.1016/j.nlm.2022.107638. Epub 2022 May 18. PMID: 35595026. 7: Stoner A, Fu L, Nicholson L, Zheng C, Toyonaga T, Spurrier J, Laird W, Cai Z, Strittmatter SM. Neuronal transcriptome, tau and synapse loss in Alzheimer's knock-in mice require prion protein. Alzheimers Res Ther. 2023 Nov 15;15(1):201. doi: 10.1186/s13195-023-01345-z. PMID: 37968719; PMCID: PMC10647125. 8: Kong Y, Cao L, Xie F, Wang X, Zuo C, Shi K, Rominger A, Huang Q, Xiao J, Jiang D, Guan Y, Ni R. Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET. Biomed Pharmacother. 2024 Mar;172:116252. doi: 10.1016/j.biopha.2024.116252. Epub 2024 Feb 6. PMID: 38325265. 9: Zheng C, Holden D, Zheng MQ, Pracitto R, Wilcox KC, Lindemann M, Felchner Z, Zhang L, Tong J, Fowles K, Finnema SJ, Nabulsi N, Carson RE, Huang Y, Cai Z. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1482-1496. doi: 10.1007/s00259-021-05597-5. Epub 2021 Nov 11. PMID: 34761284; PMCID: PMC8940841. 10: Zhang J, Wang J, Xu X, You Z, Huang Q, Huang Y, Guo Q, Guan Y, Zhao J, Liu J, Xu W, Deng Y, Xie F, Li B. In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer's disease. J Cereb Blood Flow Metab. 2023 Jun;43(6):977-988. doi: 10.1177/0271678X231153730. Epub 2023 Jan 30. PMID: 36718002; PMCID: PMC10196742. 11: Zhang J, Chen H, Wang J, Huang Q, Xu X, Wang W, Xu W, Guan Y, Liu J, Wardlaw JM, Deng Y, Xie F, Li B. Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer's disease. Alzheimers Dement. 2024 Jun;20(6):3931-3942. doi: 10.1002/alz.13845. Epub 2024 Apr 22. PMID: 38648354; PMCID: PMC11180938. 12: Chen Z, Liao G, Wan N, He Z, Chen D, Tang Z, Long Z, Zou G, Peng L, Wan L, Wang C, Peng H, Shi Y, Tang Y, Li J, Li Y, Long T, Hou X, He L, Qiu R, Chen D, Wang J, Guo J, Shen L, Huang Y, Ashizawa T, Klockgether T, Tang B, Zhou M, Hu S, Jiang H. Synaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography. Mov Disord. 2023 Jun;38(6):978-989. doi: 10.1002/mds.29395. Epub 2023 Apr 6. PMID: 37023261. 13: Hou J, Xiao Q, Zhou M, Xiao L, Yuan M, Zhong N, Long J, Luo T, Hu S, Dong H. Lower synaptic density associated with gaming disorder: an 18F-SynVesT-1 PET imaging study. Gen Psychiatr. 2023 Oct 10;36(5):e101112. doi: 10.1136/gpsych-2023-101112. PMID: 37829163; PMCID: PMC10565144. 14: Barattin M, Mattarei A, Balasso A, Paradisi C, Cantù L, Del Favero E, Viitala T, Mastrotto F, Caliceti P, Salmaso S. pH-Controlled Liposomes for Enhanced Cell Penetration in Tumor Environment. ACS Appl Mater Interfaces. 2018 May 30;10(21):17646-17661. doi: 10.1021/acsami.8b03469. Epub 2018 May 15. Erratum in: ACS Appl Mater Interfaces. 2019 Aug 14;11(32):29474-29475. doi: 10.1021/acsami.9b12730. PMID: 29737834. 15: He K, Li B, Wang J, Wang Y, You Z, Chen X, Chen H, Li J, Huang Q, Guo Q, Huang YH, Guan Y, Chen K, Zhao J, Deng Y, Xie F. APOE ε4 is associated with decreased synaptic density in cognitively impaired participants. Alzheimers Dement. 2024 May;20(5):3157-3166. doi: 10.1002/alz.13775. Epub 2024 Mar 13. PMID: 38477490; PMCID: PMC11095422. 16: Li S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, Gao H, Labaree D, Nabulsi N, Carson RE, Huang Y. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. ACS Chem Neurosci. 2019 Mar 20;10(3):1544-1554. doi: 10.1021/acschemneuro.8b00526. Epub 2018 Nov 16. PMID: 30396272; PMCID: PMC6810685. 17: Dahl K, Larsson S, Bonn P, Wallin A, Itsenko O, Schöll M. Good manufacturing procedure production of [18 F]SynVesT-1, a radioligand for in vivo positron emission tomography imaging of synaptic vesicle glycoprotein 2A. J Labelled Comp Radiopharm. 2022 Oct;65(12):315-322. doi: 10.1002/jlcr.4002. Epub 2022 Sep 8. PMID: 36044030. 18: Zheng C, Toyonaga T, Chen B, Nicholson L, Mennie W, Liu M, Spurrier J, Deluca K, Strittmatter SM, Carson RE, Huang Y, Cai Z. Decreased synaptic vesicle glycoprotein 2A binding in a rodent model of familial Alzheimer's disease detected by [18F]SDM-16. Front Neurol. 2023 Feb 8;14:1045644. doi: 10.3389/fneur.2023.1045644. PMID: 36846134; PMCID: PMC9945093. 19: Naganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, Matuskey D, Huang Y, Carson RE. First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. J Nucl Med. 2021 Apr;62(4):561-567. doi: 10.2967/jnumed.120.249144. Epub 2020 Aug 28. PMID: 32859701; PMCID: PMC8049363. 20: Wang J, Huang Q, Chen X, You Z, He K, Guo Q, Huang Y, Yang Y, Lin Z, Guo T, Zhao J, Guan Y, Li B, Xie F. Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer's disease. Mol Psychiatry. 2024 Apr 8. doi: 10.1038/s41380-024-02501-z. Epub ahead of print. PMID: 38589563.